241 related articles for article (PubMed ID: 18078997)
1. Structural characterization of a mutated, ADCC-enhanced human Fc fragment.
Oganesyan V; Damschroder MM; Leach W; Wu H; Dall'Acqua WF
Mol Immunol; 2008 Apr; 45(7):1872-82. PubMed ID: 18078997
[TBL] [Abstract][Full Text] [Related]
2. Structural characterization of a human Fc fragment engineered for extended serum half-life.
Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
[TBL] [Abstract][Full Text] [Related]
3. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).
Kainer M; Antes B; Wiederkum S; Wozniak-Knopp G; Bauer A; Rüker F; Woisetschläger M
Arch Biochem Biophys; 2012 Oct; 526(2):154-8. PubMed ID: 22634259
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
5. Structure of the murine unglycosylated IgG1 Fc fragment.
Feige MJ; Nath S; Catharino SR; Weinfurtner D; Steinbacher S; Buchner J
J Mol Biol; 2009 Aug; 391(3):599-608. PubMed ID: 19559712
[TBL] [Abstract][Full Text] [Related]
6. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
7. A variant human IgG1-Fc mediates improved ADCC.
Stewart R; Thom G; Levens M; Güler-Gane G; Holgate R; Rudd PM; Webster C; Jermutus L; Lund J
Protein Eng Des Sel; 2011 Sep; 24(9):671-8. PubMed ID: 21596686
[TBL] [Abstract][Full Text] [Related]
8. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures.
Sondermann P; Kaiser J; Jacob U
J Mol Biol; 2001 Jun; 309(3):737-49. PubMed ID: 11397093
[TBL] [Abstract][Full Text] [Related]
10. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y
Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the cooperative structure of Fc fragments from myeloma immunoglobulin G.
Tischenko VM; Abramov VM; Zav'yalov VP
Biochemistry; 1998 Apr; 37(16):5576-81. PubMed ID: 9548942
[TBL] [Abstract][Full Text] [Related]
12. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex.
Sondermann P; Huber R; Oosthuizen V; Jacob U
Nature; 2000 Jul; 406(6793):267-73. PubMed ID: 10917521
[TBL] [Abstract][Full Text] [Related]
13. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.
Matsumiya S; Yamaguchi Y; Saito J; Nagano M; Sasakawa H; Otaki S; Satoh M; Shitara K; Kato K
J Mol Biol; 2007 May; 368(3):767-79. PubMed ID: 17368483
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa.
Maxwell KF; Powell MS; Hulett MD; Barton PA; McKenzie IF; Garrett TP; Hogarth PM
Nat Struct Biol; 1999 May; 6(5):437-42. PubMed ID: 10331870
[TBL] [Abstract][Full Text] [Related]
16. Characterization and crystallization of soluble human Fc gamma receptor II (CD32) isoforms produced in insect cells.
Sondermann P; Jacob U; Kutscher C; Frey J
Biochemistry; 1999 Jun; 38(26):8469-77. PubMed ID: 10387093
[TBL] [Abstract][Full Text] [Related]
17. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
18. A C-terminal interdomain disulfide bond significantly stabilizes the Fc fragment of IgG.
Wozniak-Knopp G; Rüker F
Arch Biochem Biophys; 2012 Oct; 526(2):181-7. PubMed ID: 22483683
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation.
Ha S; Ou Y; Vlasak J; Li Y; Wang S; Vo K; Du Y; Mach A; Fang Y; Zhang N
Glycobiology; 2011 Aug; 21(8):1087-96. PubMed ID: 21470983
[TBL] [Abstract][Full Text] [Related]
20. [Interaction between CH2 and CH3-domains of human immunoglobulin G1 in glycosylated and aglycosylated Fc-fragments].
Tishchenko VM
Biofizika; 1999; 44(5):811-2. PubMed ID: 10624519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
